Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionSmall molecule attachment inhibitor that target HIV-1 gp120 and prevents its binding to CD4+ T-cells
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today